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Abstract 
Cinnabarinic and xanthurenic acids are kynurenine metabolites generated by oxidative dimerization 
of 3-hydroxyanthranilic acid and transamination of 3-hydroxykynurenine, respectively. Recent 
evidence suggests that both compounds can affect brain fuction and neurotransmission and interact 
with metabotropic glutamate (mGlu) receptors. Cinnabarinic acid behaves as an orthosteric agonist 
of mGlu4 receptors, whereas some of the effects produced by xanthurenic acid in the CNS involve 
mGlu2 and mGlu3 receptors. Cinnabarinic acid could play an important role in mechanisms of 
neuroinflammation acting as a linking bridge between the immune system and the CNS. 
Xanthurenic acid has potential implications in the pathophysiology of schizophrenia and is a 
promising candidate as a peripheral biomarker of the disorder. The action of cinnabarinic acid and 
xanthurenic acid may extend beyond the regulation of mGlu receptors and may involve several 
diverse molecular targets, such as the aryl hydrocarbon receptor for cinnabarinic acid and vesicular 
glutamate transporters for xanthurenic acid. The growing interest on these two “unorthodox” 
metabolites of the kynurenine pathway may unravel new aspects in the complex interaction between 
tryptophan metabolism and brain function, and lead to the discovery of new potential targets for the 
treatment of neurological and psychiatric disorders.   
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Abstract 
Cinnabarinic and xanthurenic acids are kynurenine metabolites generated by oxidative dimerization 
of 3-hydroxyanthranilic acid and transamination of 3-hydroxykynurenine, respectively. Recent 
evidence suggests that both compounds can affect brain fuction and neurotransmission and interact 
with metabotropic glutamate (mGlu) receptors. Cinnabarinic acid behaves as an orthosteric agonist 
of mGlu4 receptors, whereas some of the effects produced by xanthurenic acid in the CNS involve 
mGlu2 and mGlu3 receptors. Cinnabarinic acid could play an important role in mechanisms of 
neuroinflammation acting as a linking bridge between the immune system and the CNS. 
Xanthurenic acid has potential implications in the pathophysiology of schizophrenia and is a 
promising candidate as a peripheral biomarker of the disorder. The action of cinnabarinic acid and 
xanthurenic acid may extend beyond the regulation of mGlu receptors and may involve several 
diverse molecular targets, such as the aryl hydrocarbon receptor for cinnabarinic acid and vesicular 
glutamate transporters for xanthurenic acid. The growing interest on these two “unorthodox” 
metabolites of the kynurenine pathway may unravel new aspects in the complex interaction between 
tryptophan metabolism and brain function, and lead to the discovery of new potential targets for the 
treatment of neurological and psychiatric disorders.   
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1. Introduction 
 
The kynurenine pathway of tryptophan metabolism generates a series of neuroactive compounds of 
which quinolinic acid and kynurenic acid gained popularity in neuroscience for their ability to 
activate and inhibit NMDA receptors, respectively (Stone and Perkins, 1981; de Carvalho et al. 
1996; Parsons et al., 1997; Schwarcz et al., 2012). The interest in these two metabolites gave the 
wrong impression amongst neuroscientsts that the kynurenine pathway was an « inverse L », with 
the central metabolite, L-kynurenine, giving raise to kynurenic acid, or, alternatively, to a sequential 
series of metabolites that include 3-hydroxykynurenine, 3-hydroxyanthranilic acid, and quinolinic 
acid. A great emphasis was placed on two key enzymes, kynurenine monooxygenase (KMO) and 
kynurenine amino transferase, which drive the metabolic fate of L-kynurenine and tip the balance 
between kynurenic acid and quinolinic acid (reviewed by Schwarcz et al., 2012). Compounds that 
are generated « horizontally » by 3-hydroxykynurenine and 3-hydroxyanthranilic acid, i.e. 
xanthurenic acid and cinnabarinic acid, respectively (Fig. 1), have been considered as « by 
products » of the kynurenine pathway, with little or no interest for the physiology and pathology of 
the CNS. However, recent findings suggest that cinnabarinic acid and xanthurenic acid are 
neuroactive compounds, and that their actions modulate, directly or indirectly, metabotropic 
glutamate (mGlu) receptors. These receptors form a family of eight subtypes, of which the mGlu4 
receptor is targeted by cinnabarinic acid, whereas mGlu2 and mGlu3 receptors are involved in the 
action of xanthurenic acid (see below). mGlu2, mGlu3, and mGlu4 receptors are coupled to Gi/Go 
proteins and are preferentially localized at presynaptic nerve terminals, where they negatively 
regulate neurotransmitter release (reviewed by Nicoletti et al., 2011). mGlu4 receptors are also 
expressed by antigen-presenting cells, and their activation drives T cell differentiation into 
regulatory T (Treg) cells, thereby restraining autoimmunity and neuroinflammation (Falarino et al., 
2010).  The interaction with mGlu receptors, as well as other emerging mechanisms (e.g. inhibition 
of vesicular glutamate transporters by xanthurenic acid and activation of the aryl hydrocarbon - Ah 
- receptor by cinnabarinic acid) have generated new interest in these two « unorthodox » kynurenine 
metabolites. Cinnabarinic acid (2-amino-3-oxo-3H-phenoxazine-1,9-dicarboxylic acid), which is 
responsible for the anitimicrobial activity of the fungus, Pycnoporus cinnabarinus (Eggert et al., 
1997), is generated from enzymatic and non-enzymatic oxidation of 3-hydroxyanthranilic acid 
(Rao, 1966; Ogawa et al., 1983; Christen et al., 1992). Xanthurenic acid is formed by 
transamination of 3-hydroxykynurenine (Malina and Martin, 1996). In rat and human brain, 
transamination of 3-hydroxykynurenine into xanthurenic acid is catalyzed by type-2 kynurenine 
aminotransferase (Sathysaikumar et al., 2014), the same enzyme that converts kynurenine into 
kynurenic acid (reviewed by Schwarcz et al., 2012). 
This review will focus on recent findings highlighting a potential role for cinnabarinic acid and 
xanthurenic acid in CNS physiology and pathology focusing on the possible involvement of mGlu 
receptors in the mechanism of action of these compounds. 
 
2. Cinnabarinic acid 
Recent findings led to the identification of two novel receptor targets for cinnabarinic acid: (i) the 
mGlu4 receptor; and (ii) the aryl hydrocarbon (Ah) receptor. Interestingy, both receptors have been 
implicated in mechanisms that lie at the core of neuroinflammation, by regulating the bidirectional 
communication between antigen presenting cells (APCs) and T lymphocytes at the immunological 
synapse (reviewed by Volpi et al., 2012). In collaboration with the research groups of Jean-Phlippe 
Pin and Cyrille Goudet (University of Montpellier, France), and Francine Acher (University Renè 
Descartes, Paris, France) we have found that cinnabarinic acid behaves as a weak orthosteric 
agonist of mGlu4 receptors, with no activity at other mGlu receptor subtypes (Fazio et al., 2012). 
mGlu4 receptors are coupled to Gi/o GTP-binding proteins, and are localized on presynaptic 
terminals where they negatively regulate neurotransmitter release (reviewed by Nicoletti et al., 
2011). Selective positive allosteric modulators (PAMs) of mGlu4 receptors are under development 
for the treatment of Parkinson’s disease (reviewed by Nickols and Conn, 2014; Walker and Conn, 
2015), and are potential candidate drugs for the treatment of neuropathic pain (Goudet et al., 2008). 
Of note, mGlu4 receptors are also expressed by APCs and T lymphocytes (Fallarino et al., 2010; 
see below).  
Cinnabarinic acid acts as a partial agonist in cell clones expressing mGlu4 receptors by interacting 
with the glutamate binding pocket localized in the N-terminus Venus Fly Trap domain of the 
receptor. In addition, cinnabarinic acid inhibits cAMP formation in cultured cerebellar granule cells, 
which are known to express large amounts of mGlu4 receptors (Santi et al., 1994), and the cAMP 
response to low concentrations of cinnabarinic acid is abolished in cultures prepared from mGu4 
receptor knockout mice (Fazio et al., 2012). Cinnabarinic acid attenuates excitotoxic neuronal death 
in cultured cortical cells, and protects nigro-striatal neurons against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) toxicity  when locally infused into the mouse external globus pallidus 
(Fazio et al., 2012), thus mimicking the action of conventional mGlu4 receptor agonists (Maj et al., 
2003; Battaglia et al., 2006). These findings indicate that cinnabarinic acid is able to activate native 
mGlu4 receptors in the CNS. However, most of the effects seen in cultured neurons require 
concentrations of cinnabarinic acid >10-30 mM (Fazio et al., 2012), and this casts doubt on the 
physiological relevance of the interaction beween cinnabarinic acid and neuronal mGlu4 receptors. 
Under normal conditions, brain cinnabarinic acid is barely detectable in the mouse brain, but its 
levels dramatically increase (up to >150 pg/mg tissue) in response to systemic injection of 
lipopolysaccharide (LPS), which is known to cause neuroinflammation (Fazio et al., 2012). It is 
possible that cinnabarinic acid formed as a by-product of the kynurenine pathway activated in 
response to neuroinflammation serves as an endogenous protective agent that restrains synaptopathy 
and neuronal damage caused by pro-inflamatory cytokines secreted by immune cells or by resident 
astrocytes and microglia. This attractive hypothesis warrants further investigation. 
The evidence that the mGlu4 receptor is involved in mechanisms regulating the fate of T cells at the 
immune synapse (Fallarino et al., 2010) has provided new insights into the role played by mGlu4 
receptors in neuroinflammation.  The mGlu4 receptor is expressed in dendritic cells, and its 
activation tips the balance of Th cell differentiation in favour of a Treg immune tolerant phenotype. 
As a result of this mechanism, systemic treatment with the mGlu4 receptor PAM, (-)-N-phenyl-7-
(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC), protects mice against the 
development of experimental autoimmune encephalomyelitis (EAE, an experimental animal model 
of multiple sclerosis), whereas mice lacking mGlu4 receptors show a more severe form of EAE in 
response to immunization with a myelin-related antigen (Fallarino et al., 2010). A more recent 
study has confirmed these findings showing that compound ADX88178, a novel mGlu4 receptor 
PAM endowed with high potency and selectivity and optimized PK profile, protects mice against 
EAE and stimulates dendritic cells to produce tolerogenic cytokines, such as interleukin-10 and 
transforming growth factor-b via a Gi-independent signaling pathway that involves 
phosphatidylinositol-3-kinase, the tyrosine kinase, Src, and type-1 indoleamine 2,3-dioxygenase 
(IDO-1) (Volpi et al., 2016). The evidence that activation of mGlu4 receptors directs Th 
differentiation toward Treg cells at the expense of Th17 cells (Falarino et al., 2010) laid the 
groundwork for the study of cinnabarinic acid in EAE mice. Systemic treatment of cinnabarinic 
acid (0.1-10 mg/kg, i.p.) protected against MOG35-55 (fragment 35-55 of the mlyelin 
oligodendrocyte glycoprotein)-induced EAE by boosting an immune response dominated by Treg 
cells (Fazio et al., 2014). However, this action of cinnabarinic acid was only partially reduced in 
mGlu4 knockout mice, suggesting that cinnabarinic acid recruits additional targets to regulate 
immune function and restrain neuroinflammation. A growing body of evidence indicates that the Ah 
receptor is a major target for cinnabarinic acid in the modulation of the immune system. The Ah 
receptor is a ligand-dependent transcription factor that owes its name to its interaction with aromatic 
hydrocarbons, such as benzopyrene, 3-methylcolanthrene, and 2,3,7,8-tetrachlorodibenzo-p-dioxin. 
Binding of aromatic hydrocarbons to Ah receptors induces the expression of genes encoding for 
enzymaes involved in xenobiotic metabolism, such as CYP1A1 and CYP1A2. Besides this 
established function, the Ah receptor has an emerging role in the regulation of the immune system 
promoting T cell differentiation into Treg or Th17 cells depending on the receptor ligand (reviewed 
by Fallarino et al., 2014). Recent evidence indicates that Ah receptor activation mediates immune 
tolerance to bacterial endotoxins via IDO-1 signaling activity (Bessede et al., 2014). The Ah 
receptor is targeted by a series of tryptophan metabolites that includes L-kynurenine and kynurenic 
acid (Mezrich et al., 2010; Nguyen et al., 2010; Maaetoft-Udsen et al., 2012; Stephens et al., 2013; 
Kawasaki et al., 2014; Nuti et al., 2014). Using the expansion of interleukin-22 producing cells as a 
read-out system, Lowe et al. (2014) have found that cinnabarinic acid acts as an endogenous agonist 
of Ah receptors. Interestingly, cinnabarinic acid was more effective than L-kynurenine or kynurenic 
acid in inducing interleukin-22 but less effective in inducing CYP1A1 in mouse or human T 
lymphocytes (Lowe et al., 2014). Thus, by analogy with estrogen and progesterone receptor ligands, 
cinnabarinic acid might be defined as a selective Ah receptor modulator (SAhRM) (Lowe et al., 
2014). Mechanisms of ligand- and signaling-bias at the Ah receptors might drive the pattern of the 
cellular response of the Ah receptor to different kynurenine metabolites in the regulation of 
xenobiotic metabolism and immune function. It will be interesting to establish how mGlu4 and Ah 
receptors contribute to the overall response of immune cells to cinnabarinic acid taking into account 
that other endogenous ligands, such as glutamate for mGlu4 and tryptophan metabolites for Ah 
receptors, might compete with cinnabarinic acid for receptor binding, thereby shaping the cellular 
response to cinnabarinic acid.  
Interestingly, activation of Ah receptors by cinnabarinic acid protects cultured hepatocytes against 
apoptosis induced by ethanol, hydrogen peroxide, and thapsigargin. This effect is mediated by the 
induction of stanniocalcin-2, a putative secreted glycophosphoprotein that has shown protective 
activity against endoplasmic reticulum and oxidative stress (Joshi et al., 2015). Whether this 
mechanism contributes to the neuroprotective activity of cinnabarinic acid against excitotoxic 
neuronal death (Fazio et al., 2012) remains to be determined.    
 
3. Xanthurenic acid 
 
Xanthurenic acid has been the subject of multidisciplinary studies, which address inter alia its role 
in apoptotic cell death (Malina et al., 2001 ; Malina and Hess, 2004), regulation of natriuresis (Cain 
et al., 2007 ; Hoffman et al., 2013), regulation of insulin secretion and activity (Oxenkrug et al., 
2013), and activation of gametogenesis in Plasmodium species (Garcia et al., 1998). Gobaille et al. 
(2008) have shown that xanthurenic acid meets the criteria to be considered as a putative 
neurotransmitter. Xanthurenic acid is present in micromolar amounts in the rat brain, is stored in 
synaptic vesicles, released by depolarizing stimuli in a Ca
2+
-dependent fashion, and actively 
transported by a neuronal sodium/chloride symporter (Gobaille et al., 2008). [
3
H]Xanthurenic acid 
binds to specific and saturable recognition sites in brain membranes, and specifically bound 
[
3
H]xanthurenic acid is displaced by picolinic acid and, to a lesser extent, by kynurenic acid and 
quinolinic acid (Taleb et al., 2012). In addition, low micromolar concentrations of xanthurenic acid 
enhance [
35
S]GTP-g-S binding in crude synaptosomal preparations, suggesting that xanthurenic acid 
binds to a G-protein coupled receptor (Taleb et al., 2012). The identity of this receptor is unknown 
at present. A series of studies have examined the possibility that xanthurenic acid interacts with 
group-II mGlu receptors (mGlu2 and mGlu3 receptors). Intravenous injection or local iontophoretic 
application of xanthurenic acid reduced sensory inhibition of ventrobasal thalamic neurons 
mediated by the activation of reticular thalamic neurons (Copeland et al., 2013). Xanthurenic acid 
only partially mimicked the action of the prototypical mGlu2/3 receptor agonist, (1S,2S,5R,6S)-2-
aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), because the action of both 
compounds was attenuated by the preferential mGlu2/3 receptor antagonist, 2-[(1S,2S)-2-
carboxycyclopropyl]-3-(9H-xanthen-9-yl)-D-alanine (LY341495), but only the action of LY354740 
was potentiated by the mGlu2 receptor enhancer, N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethylamine (LY487379) (Copeland et al., 2013).  In contrast, 
inhibition of synaptic transmission by xanthurenic acid was insensitive to LY341495 in rat 
hippocampal slices, and, as opposed to LY354740, xanthurenic acid failed to  reduce paired-pulse 
depression in the hippocampal dentate gyrus (Neale et al., 2013). It was concluded that xanhurenic 
acid does not directly interact with mGlu2 or mGlu3 receptors  (see below). However, xanthurenic 
acid displayed a high potency in activating mGlu2 and mGlu3 receptors in transfected HEK293 
cells showing no activity at recombinant mGlu4- or mGlu7 receptors (Fazio et al., 2015). In mouse 
cortical cells, xanthurenic acid mimicked the action of mGlu2/3 receptor agonists in inhibiting 
cAMP formation, and its action was sensitive to LY341495 and attenuated by genetic deletion of 
mGlu2 receptors (Fazio et al., 2015). Specifically bound [
3
H]xanthurenic acid was not displaced by 
mGlu2/3 receptor ligands in brain membranes, and xanthurenic acid did not inhibit [
3
H]LY341495 
binding in brain membranes (Fazio et al., 2015) and in membranes stably expressing human mGlu2 
receptors (Neale et al., 2013). Interestingly, however, specific [
3
H]xanthurenic acid binding could 
be detected in membranes prepared from mGlu2- or mGlu3-expressing HEK-293 cells, but not in 
membranes prepared from mock cells or from mGlu4-expressing cells (Fazio et al., 2015). It is 
difficult to formulate a single hypothesis that may uniformely explain all these findings. It appears 
clear that xanthurenic acid does not directly interact with the glutamate binding pocket of mGlu2 
and mGlu3 receptors. It cannot be exlluded that xanthurenic acid acts as a allosteric agonist (i.e., an 
allosteric compound endowed with intrinsic efficacy) of mGlu2/3 receptors, but this does not 
explain why inhibition of field excitatory post-synaptic potentials (fEPSP) by xanthurenic acid in 
hippocampal slices was insensitive to pharmacological blockade of mGlu2/3 receptors (Neale et al., 
2013). Xanthurenic acid might interact with its own receptor (perhaps a not-yet identified G-protein 
coupled receptor), which may engage mGlu2/3 receptor signaling and  might also signal via other 
mechanisms. Perhaps, the most likely explanation for some of the observed effects of xanthurenic 
acid (Neale et al., 2013) is that the compound targets other mechanisms regulating glutamatergic 
neurotransmission. Interestingly, xanthurenic acid inhibits vesicular glutamate transporters 
(VGLUTs) (Bartlett et.al. 1998), thereby preventing glutamate uptake into synaptic vesicles (see 
Neale et al., 2014). A series of structurally unrelated VGLUT inhibitors, such as Rose Bengal, 
Congo Red, and Chicago Sky Blue 6B, shares with xanthurenic acid the ability to depress fEPSPs at 
the Schaffer collateral-CA1 pyramidal cell synapses (Neale et al., 2014), and to reduce the 
amplitude of fEPSPs recorded in the dentate gyrus (Neale et al., 2013). Thus, it is possible that, at 
least in distinct CNS regions, xanthurenic acid inhibits glutamatergic transmission by blocking 
transport of L-glutamate into synaptic vescicles thereby ultimately reducing the synaptic release of 
L-glutamate. 
The mGlu2 receptor has been implicated in the pathophysiology of schizophrenia (Moghaddam and 
Adams, 1998; Aghajanian and Marek, 2000; Marek et al., 2000; Gonzales-Maeso et al., 2008; 
Moreno et al., 2016; Holloway et al., 2013; reviewed by Delille et al., 2013), and both mGlu2/3 
orthosteric agonists and mGlu2 receptor PAMs show efficacy in experimental animal models that 
are predictive of antipsychotic activity (Fell et al., 2012; Hiyoshi et al., 2014; Walker and Conn, 
2015). An exploratory analysis of clinical studies showed that pomeglumetad methionyl (the oral 
prodrug of the mGlu2/3 receptor agonist, LY404039) was effective in relieving both positive and 
negative symptoms in subgroups of patients affected by schizophrenia who were early in disease  
and had not been previously treated with atypical antipsychotics (Kinon et al., 2015). Xanthurenic 
acid displayed antipsychotic-like activity in mice challenged with [5R,10S]-[+]-5-methyl-10,11-
dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801) via the activation of mGlu2 receptors 
(Fazio et al., 2015). Interestingly, bood levels of xanthurenic acid were substantially reduced in a 
large cohort of patients affected by schizophrenia. This reduction persisted after months of 
treatment with antipsychotic drugs and was also observed in first-degree relatives of patients 
affected by schizophrenia (Fazio et al., 2015). Other kynurenine metabolites that lie downstream of 
KMO, such as 3-hydroxykynurenine, 3-hydroxyanthranilic acd, and quinolinic acid were also 
reduced in the blood of patients affected of schizophrenia, as expected (Erhardt et al., 2001; 
Linderholm et al., 2012; Schwarcz et al., 2012; Kegel et al., 2014), but only xanthurenic acid and 3-
hydroxyanthranilic acid were reduced in first-degree relatives of patients (Fazio et al., 2015). These 
findings suggest that (i) a reduction of xanthurenic acid production might contribute to the 
pathophysiology of schizophrenia by restraining the endogenous activation of mGlu2 receptors; 
and, (ii) blood levels of xanthurenic acid might represent a new peripheral biomarker that may 
allow the indentification of individuals at risk of developing schizophrenia. Such individuals might 
then be able to receive disease-modifying treatments in the early phases of the disorder. Blood 
levels of xanthurenic acid are also lower in patients affected by attention deficit and hyperactivity 
disorder (ADHD) (Aarsland et al., 2015) and cluster headache (Curto et al., 2016a), and are higher 
in patients affected by chronic migraine (Curto et al., 2016b). However, these changes are small and 
their biological significance is uncertain.  
The discovery that xanthurenic acid is a potent inhibitor of sepiapterin reductase (Haruki et al., 
2016) indicates that the function of xanthurenic acid in the CNS extends beyond the regulation of 
membrane transporters or neurotransmitter receptors. Sepiapterin reductase is the final enzyme in 
the de novo synthesis of tetrahydrobiopterin, the enzymatic cofactor of tyrosine hydroxylase, 
tryptophane hydroxylase, and nitric oxide synthase. This mechanism might limit the stimulation of 
tetrahydrobiopterin synthesis caused by pro-inflammatory cytokines (which also induce the 
kynurenine pathway), and might aso contribute to explain the psychiatric adverse effects of 
interferon treatment (Haruki et al., 2016). Inhibition of tetrahydrobiopterin synthesis by xanthurenic 
acid might also pave the way to the design of new drugs aimed at restraining dopamine or serotonin 
synthesis in psychiatric disorders such as drug addiction and schizophrenia.    
 
Conclusions 
It is becoming clear that many members of the kynurenine pathways can have complex effects in 
physiological systems both within the brain and in other parts of the body.  In particular, both 
cinnabarinic acid and xanthurenic acid appear to be able to affect several diverse molecular targets 
and signaling systems that are only beginning to be uncovered.  What is clear, however, is that these 
compounds can affect brain function and neurotransmission in a variety of ways, and that this may 
be altered under pathological conditions.  Thus, future studies on the function of cinnabarinic acid 
and xanthurenic acid will no doubt result in better understanding of disease processes and may 
reveal new potential therapeutic targets in nervous system diseases. 
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Figure legend 
Fig. 1 – The kynurenine pathway with highlight on cinnabarinic acid and xanthurenic acid. 
IDO = indoleamine 2,3-dioxygenase ; TDO = tryptophan 2,3-dioxygenase ; KATs = kynurenine 
aminotransferases ; KMO = kynurenine monooxygenase ; 3-HAO = 3-hydroxyanthranilic acid 3,4-
dioxygenase.   
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